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1 |  INTRODUCTION
Chronic Q fever is a persistent infection with the intracel-
lular bacterium Coxiella burnetii, which affects individu-
als with pre‐existing heart valve abnormalities, aneurysms, 
aortic prostheses, a compromised immune system or preg-
nancy.1 After the major Q fever outbreak in the Netherlands 
(2007‐2011), chronic Q fever patients presented with diverse 
clinical symptoms and complications. The infection is severe, 
life‐threatening and can be associated with immunological 
phenomena and autoimmune diseases.2,3
Systemic sclerosis (SSc) is a complex immune disorder 
with an unknown pathogenesis. It has three distinctive hall-
marks: inflammation, vasculopathy and extensive fibrosis. 
Clinically, these hallmarks are expressed as progressive fi-
brosis of skin and internal organs, digital ulcera, pulmonary 
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Abstract
Background: After the Q fever outbreak in the Netherlands between 2007 and 2010, 
more than 300 patients with chronic Q fever have been identified. Some patients 
were also diagnosed with systemic sclerosis, a rare immune‐mediated disease. We 
aimed to increase awareness of concomitant chronic Q fever infection and systemic 
sclerosis and to give insight into the course of systemic sclerosis during persistent Q 
fever infection.
Materials and methods: Chronic Q fever patients were identified after the Dutch 
Q fever outbreak in 2007‐2010. Systemic sclerosis was diagnosed by a scleroderma 
expert and patients fulfilled the 2013 Classification Criteria for Systemic Sclerosis.
Results: Four cases presented with chronic Q fever, persistent Coxiella burnetii 
infection, shortly preceded or followed by the diagnosis of limited cutaneous sys-
temic sclerosis. The three male patients of 60 years or older developed a relatively 
mild systemic sclerosis, which did not require immunosuppressive therapy during 
adequate treatment of the chronic Q fever infection. The 58‐year‐old female patient 
used immunosuppressives for her newly diagnosed systemic sclerosis at the time she 
likely developed a chronic Q fever infection.
Conclusions: In this case series, chronic Q fever preceding systemic sclerosis was 
associated with a mild course of systemic sclerosis without the necessity of immuno-
suppressive drugs, while chronic Q fever development due to immunocompromised 
state was associated with a more deteriorating course of systemic sclerosis.
K E Y W O R D S
chronic Q fever, Coxiella burnetii, persistent focalized Q fever infection, systemic sclerosis
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal 
Foundation
2 of 5 |   JANSEN Et Al.
arterial hypertension, interstitial lung disease and renal 
disease. Infectious agents have long been implicated in the 
pathology of SSc, and different views exist on how they con-
tribute to the development of SSc.4 One of those is the dis-
covery of the interferon signature in patients with SSc, which 
implies that innate immunity is imperative in the disease pro-
cess.5 While chronic viral infections have been postulated to 
be involved in the development of SSc, this link is not firmly 
established for bacterial infections.6 Until now, SSc has not 
been associated with Q fever.
We report four cases of chronic Q fever coinciding with 
SSc, although presentation and diagnostic course varied 
greatly. By reporting these four cases, we aim to raise aware-
ness for the concomitant occurrence of chronic Q fever and 
systemic sclerosis.
2 |  METHODS
Patients were identified after the Dutch Q fever outbreak 
in 2007‐2010. Chronic Q fever was diagnosed in patients 
with a positive PCR for C  burnetii in blood or tissue, or 
IgG phase I titres measured by immunofluorescence assay 
(IFA) of ≥1:1024 and a definite endocarditis according to the 
modified Duke criteria or proven large vessel or prosthesis 
infection. Patients with IgG phase I titres of ≥1:1024 and 
immunosuppressive drug use were classified as “probable”.7 
SSc was diagnosed by a scleroderma expert and patients ful-
filled the 2013 Classification Criteria for Systemic Sclerosis. 
All patients or their legal representatives provided written 
informed consent for publication. Patients characteristics are 
described in Table 1.
3 |  RESULTS
3.1 | Patient 1
This 62‐year‐old man was diagnosed with chronic Q fever in 
November 2009 after several months of malaise with bouts 
of fever. He had recently been diagnosed with an aortic aneu-
rysm, which was treated with an endovascular aneurysm re-
pair (EVAR). His anti‐C burnetii phase I IgG antibodies were 
1:4096, indicative of a chronic Q fever infection. Pus removed 
around the EVAR during another operative procedure was 
PCR‐positive for C burnetii. He was started on doxycycline 
200 mg and hydroxychloroquine 600 mg. In the same month, 
the patient was referred to a dermatologist because of red pur-
puric lesions on his toes. A skin biopsy unveiled superficial 
and deep perivascular chronic dermatitis with signs of a vas-
culopathy, a lymphocytic infiltrate and a thickened vascular 
T A B L E  1  Patient characteristics
  Patient 1 Patient 2 Patient 3 Patient 4
Gender Man Man Man Woman
Age 62 years 68 years 63 years 58 years
Deceased Yes No No Yes
Q fever‐related characteristics
Q fever status Proven Proven Proven Probable
Diagnosis 11 2009 09 2016 11 2016 09 2009 (already positive serol-
ogy in 2007)
IgG phase I at 
diagnosis
1:4096 1:8192 1:1024 1:8192
Focus of infection Vascular Vascular Vascular Unknown
Prosthesis EVAR None EVAR None
Complications – EVAR for aneurysm 
expansion
Abscesses –
PCR Tissue positive Blood negative Blood negative Blood negative
Treatment 
duration
24 months Ongoing > 24 months Ongoing > 23 months 26 months
Scleroderma‐related characteristics
Diagnosis 09 2010 01 2012 04 2017 03 2007
Symptoms at first 
visit
Raynaud's phenomenon, red 
purpuric lesions, facial tel-
eangiectasia, nailfold lesions
Raynaud's phenom-
enon, nailfold lesions
Raynaud's phenom-
enon, puffy fingers, 
nailfold lesions
Raynaud's phenomenon, sclero-
dactyly, interstitial lung disease
mRSS at first visit 9 0 0 2
Autoantibodies ANA, ACA ANA, ACA, pANCA ANA, anti‐Scl‐70 ANA, ENA, anti‐SSA
   | 3 of 5JANSEN Et Al.
wall. A rheumatologist diagnosed him with limited cutane-
ous systemic sclerosis (LcSSc), which was based on positive 
antinuclear antibodies (ANA), positive anticentromere anti-
bodies (ACA), skin sclerosis, Raynaud's phenomenon, facial 
teleangiectasia and nailfold capillaroscopic changes consist-
ent with an active scleroderma pattern. The modified Rodnan 
skin score (mRSS), which is used to monitor the extensive-
ness of skin involvement, was nine at his first visit. There 
were no signs of organ involvement. Therapy was not started 
due to the relatively mild complaints. During follow‐up visits, 
the patient presented with digital ulcera and sclerodactyly. In 
November 2011, anti‐C burnetii phase I antibody titres had 
sufficiently decreased to 1:128 and the treatment for chronic 
Q fever was stopped. The LcSSc remained uneventful.
3.2 | Patient 2
This 68‐year‐old man was referred to the outpatient clinic of the 
Rheumatology department on suspicion of systemic sclerosis by 
his general physician in January 2012. His medical history re-
vealed arterial and venous insufficiency with venous thrombosis 
and pulmonary emboli in 2011. Since 4 years, he experienced 
Raynaud's phenomenon and recently started to feel the skin of 
his fingers thicken. The mRss was 0 at that time. Nailfold capil-
laroscopy, however, demonstrated an early scleroderma pattern 
with dilated loops, irregular structure and micro‐haemorrhages. 
His laboratory parameters revealed positive ANA and anticen-
tromere antibodies. He was diagnosed with early LcSSc, and 
nifedipine 2 dd 40 mg was prescribed for his Raynaud's phe-
nomenon. Gradually, sclerodactyly developed and his mRss in-
creased to 2 in 2014. There were no signs of pitting scars, digital 
ulcera or internal organ involvement. Meanwhile in 2013, an 
aortic aneurysm was discovered and follow‐up visits were per-
formed yearly. An FDG PET/CT scan performed in September 
2016 showed an aneurysm with surrounding infected soft tissue. 
Upon this finding, anti‐C burnetii phase I IgG antibodies were 
determined and a highly increased titre of 1:8192 was detected, 
and PCR for C burnetii on blood was negative. Chronic Q fever 
was diagnosed, and he was started with doxycycline and hy-
droxychloroquine therapy. In July 2017, his mRSS was 3, based 
on skin thickening of the fingers and lower arm. Due to a sudden 
expansion of his aneurysm, an EVAR was performed. He is cur-
rently still being treated and monitored for his chronic Q fever 
infection and LcSSc, respectively.
3.3 | Patient 3
In 2016, a 63‐year‐old man received an EVAR for his 
recently identified aneurysm of the abdominal aorta and 
distal common iliac artery. Although he had an unremark-
able medical history before surgery, he experienced night 
sweats and lost 15% of his initial weight after surgery. 
Anti‐C burnetii phase I IgG titre was found to be 1:1024, 
and an infected EVAR with abscesses was visualized on an 
FDG PET/CT scan. PCR on blood and drained pus from a 
perianal abscess remained negative for C burnetii. He was 
started on doxycycline and hydroxychloroquine. Because 
the abscesses around the iliac artery were closely related 
to the rectosigmoid junction and cultured different intes-
tinal bacteria, a fistula was suspected. In a routine screen-
ing, autoantibodies were determined and revealed positive 
ANA and anti‐topoisomerase I antibodies (anti‐Scl‐70). 
The patient appeared to have a new onset of Raynaud's 
phenomenon and mild puffy fingers. Nailfold capillaros-
copy showed aspecific changes consisting of a normal cap-
illary density, micro‐haemorrhages and broadening of the 
apexes. Giant capillaries were not present. Based on these 
clinical data, the patient was diagnosed with early SSc and 
is currently being monitored in the outpatient clinic.
3.4 | Patient 4
This 58‐year‐old woman presented with increasing complaints 
of discoloured fingers and toes at the outpatient clinic of the 
Rheumatology department in 2007. Upon physical investiga-
tion, radial folds around the mouth were discovered. She evi-
dently suffered from swollen fingers with sclerodactyly and 
thickened cuticles accounting for a mRSS of 2. Laboratory 
investigation showed a sedimentation rate of 24 mm/h and 
the presence of ANA. She was diagnosed with LcSSc based 
on sclerodactyly, Raynaud's phenomenon, ANA positivity, 
an early scleroderma pattern on nailfold capillaroscopy and 
interstitial lung diseases. She was shortly prescribed metho-
trexate (20 mg weekly), but this was stopped due to disease 
progression under therapy. Prednisone 10 mg daily was 
started, although this also failed to result in remission of the 
disease. In 2008, her mouth orifice was further limited, and 
she presented with a polyarthritis of both knees, metacarpal 
phalanx (MCP) I, and PIP III and IV. Methotrexate 20 mg 
weekly was again started in September 2008 without any im-
provement. Therefore, 120 mg intramuscular methylpredni-
solone injections every 6 weeks were initiated.
Meanwhile, in 2008, she was admitted with a presumed 
acute Q fever infection based on positive anti‐C burnetii IgG, 
for which she was prescribed doxycyline 100 mg twice daily 
for 2 weeks. In January 2009, IgG phase I titres were again 
tested and turned out to be 1:8192. Retrospectively, IgG 
phase I titres from serum in 2007 were already 1:4096. She 
was diagnosed with probable chronic Q fever,7 based on high 
serology titres and the immune suppressants she had used 
around 2007. A focus for the infection could not be identified.
With regard to the LcSSc, her condition gradually dete-
riorated, borderline pulmonary hypertension was diagnosed, 
and methotrexate was prescribed in addition to prednisone, 
despite the chronic infection. The serologic titres slowly de-
clined fourfold with doxycycline and hydroxychloroquine, 
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which were stopped after 2 years of treatment in 2011, when 
anti‐C burnetii IgG phase I was 1:2048.
4 |  DISCUSSION
The present study describes four chronic Q fever patients with 
concomitant LcSSc, differing in presentation and diagnostic 
process. In all four cases, the Q fever infection coincided 
with the beginning or worsening of SSc symptoms, although 
the disease entities were not diagnosed simultaneously. The 
Q fever outbreak in the Netherlands,8 which started in 2007 
and ended in 2010, offered a well‐defined time frame in 
which Q fever was most likely contracted, as before and after 
the outbreak, incidence levels were neglectably low. Most 
patients, however, already had Raynaud's phenomenon for 
a longer period of time, indicating that they likely had an 
increased susceptibility for SSc, the onset of which was pos-
sibly triggered by the chronic Q fever infection. The three 
male patients developed a relatively mild disease, which did 
not require immunosuppressive therapy. Furthermore, with 
adequate treatment of the chronic Q fever infection, the SSc 
remained present.
The prevalence of systemic sclerosis in the Netherlands 
is 8.9 per 100 000 adults.9 After the Q fever outbreak in the 
Netherlands, the prevalence of systemic sclerosis among 
proven and probable chronic Q fever patients is 4 in 322 
individuals (unpublished data from Q fever database). 
Extrapolating these numbers (1242:100 000), this indicates 
a possible association between chronic Q fever and systemic 
sclerosis. Although this is a highly selected group of indi-
viduals, bias based on population characteristics is unlikely. 
Supportive of this notion is that systemic sclerosis is usually 
more prevalent among women, while chronic Q fever is not, 
and systemic sclerosis is generally diagnosed earlier (me-
dian of 50 years),9 compared to chronic Q fever (median of 
71 years).10 Silica exposure is a known environmental risk 
factor for the development of systemic sclerosis, and stud-
ies indicate that the percentage of previous environmental 
risk factor exposure is especially high in men with systemic 
sclerosis.11
It is documented that chronic Q fever infection can trig-
ger autoimmune diseases and other immunological syn-
dromes.2,3 In favour of this is the typically older age of onset 
and the male gender of the cases, both features that are more 
commonly seen in chronic Q fever than SSc.1 Furthermore, 
an increasing body of evidence suggests that infectious 
agents can trigger SSc, for example, antibodies to cyto-
megalovirus, parvovirus B19, hepatitis B, Toxoplasma and 
Helicobacter pylori are more common in SSc patients than 
in matched control groups.12-15 The mechanisms for this have 
yet to be elucidated, but among others, molecular mimicry 
seems conceivable, as retroviral proteins show similarity to 
topoisomerase antigen.16 Molecular mimicry has not yet been 
examined for C burnetii. Generally, loss of self‐tolerance un-
derlies autoimmune diseases and may be provoked by exces-
sive inflammation. The possible mechanism for autoantibody 
production remains elusive in many infectious diseases that 
predispose to autoimmune syndromes. With regard to Q fever, 
intriguingly, C burnetii infection and SSc both share the acti-
vation of the interferon type I pathway in dendritic cells.17,18 
Not excluding other theories, C burnetii might also facilitate 
the progression of early systemic sclerosis, possibly through 
the induction of CXCL10 and CXCL11. These chemokines 
are abundantly produced by immune cells of chronic Q fever 
patients 19 and are biomarkers for disease progression of early 
SSc.20,21 Interesting in this notion is that CXCL10, induced 
by TNFα, interferons and fibroblasts, is anti‐angiogenic and 
promotes vascular smooth muscle cell proliferation.22
This study shows that chronic Q fever can coincide with 
systemic sclerosis, but a causal interaction cannot be de-
ducted from this case series. Larger prospective studies 
among chronic Q fever patients would be needed to prove 
any causal relationship, but these are highly unlikely due to 
the rarity of this disease.
Evidently differing from the other cases, case 4 suffered 
from LcSSc with interstitial lung disease that required im-
munosuppressive therapy. Here, effective treatment of the 
infection did not noticeably improve the course of the SSc. 
Whether Q fever or SSc precedes the other is unclear, but 
both scenarios seem plausible. It is known that rheumatoid 
arthritis patients have an increased risk for the development 
of chronic Q fever, while anti‐tumour necrosis factor (TNF) 
therapy was found not to be an independent risk factor.23
This case series describes the coincidence of chronic Q 
fever and systemic sclerosis, but the role of chronic Q fever in-
fection in the pathogenesis or disease progression of systemic 
sclerosis remains to be elucidated. The three male patients di-
agnosed after 60 years of age showed mild SSc in the absence 
of immunosuppressive therapy, while the female patient pre-
sented with a more aggressive course of SSc, possibly due to a 
non‐Q fever‐related aetiology. By describing these four cases, 
we would like to raise awareness for concomitant chronic Q 
fever and systemic sclerosis and their clinical course.
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